Skip to content
1887

Journal of General Virology header logo Journal of General Virology

Volume 106, Issue 11

Inhibition of human cytomegalovirus replication by valaciclovir Open Access

Abstract

Vertical transmission of human cytomegalovirus (HCMV) during pregnancy is a major cause of congenital disease. In the absence of robust vaccination strategies, antiviral drug regimens are being developed to inhibit the vertical transmission of the virus. Recent clinical data have indicated that valaciclovir, an orally bioavailable form of aciclovir, was effective at limiting vertical transmission of HCMV when administered during pregnancy. However, there is no widely cited analysis of valaciclovir’s antiviral effect against HCMV, and it is possible, like aciclovir, that valaciclovir has poor anti-HCMV activity. The antiviral effects of aciclovir and valaciclovir against HCMV were compared to the widely used anti-HCMV drug ganciclovir. Compared to ganciclovir, the anti-HCMV effects of either aciclovir or valaciclovir were poor, and robust anti-HCMV activity in all cell lines tested (adult fibroblast, foetal fibroblast or trophoblast cells) was only observed at high drug concentrations. All drugs had no obvious effects on the viability of uninfected cells. Overall, valaciclovir had poor anti-HCMV activity, and its anti-HCMV efficacy upon administration during pregnancy may rely on a combination of factors. These data argue for the continued development of valaciclovir and anti-HCMV compounds to inhibit vertical virus transmission.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): cytomegalovirus , drug , pregnancy and valaciclovir
Funding
This study was supported by the:
  • St. George's, University of London
    • Principal Award Recipient: BlairL Strang
© 2025 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License. This article was made open access via a Publish and Read agreement between the Microbiology Society and the corresponding author’s institution.
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.002178
2025-11-14
2025-12-16

Metrics

Loading full text...

Full text loading...

/deliver/fulltext/jgv/106/11/jgv002178.html?itemId=/content/journal/jgv/10.1099/jgv.0.002178&mimeType=html&fmt=ahah

References

  1. Jones CE, Bailey H, Bamford A, Calvert A, Dorey RB et al. Managing challenges in congenital CMV: current thinking. Arch Dis Child 2023; 108:601–607 [View Article] [PubMed]
     [Google Scholar]
  2. Coyne CB, Lazear HM. Zika virus - reigniting the TORCH. Nat Rev Microbiol 2016; 14:707–715 [View Article] [PubMed]
     [Google Scholar]
  3. Griffiths P, Reeves M. Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat Rev Microbiol 2021; 19:759–773 [View Article] [PubMed]
     [Google Scholar]
  4. Griffiths P. The direct and indirect consequences of cytomegalovirus infection and potential benefits of vaccination. Antiviral Res 2020; 176:104732 [View Article] [PubMed]
     [Google Scholar]
  5. Coen DM, Schaffer PA. Antiherpesvirus drugs: a promising spectrum of new drugs and drug targets. Nat Rev Drug Discov 2003; 2:278–288 [View Article] [PubMed]
     [Google Scholar]
  6. Strang BL. Toward inhibition of human cytomegalovirus replication with compounds targeting cellular proteins. J Gen Virol 2022; 103: [View Article] [PubMed]
     [Google Scholar]
  7. Sullivan V, Talarico CL, Stanat SC, Davis M, Coen DM et al. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 1992; 358:162–164 [View Article] [PubMed]
     [Google Scholar]
  8. Talarico CL, Burnette TC, Miller WH, Smith SL, Davis MG et al. Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein. Antimicrob Agents Chemother 1999; 43:1941–1946 [View Article]
     [Google Scholar]
  9. Chen H, Beardsley GP, Coen DM. Mechanism of ganciclovir-induced chain termination revealed by resistant viral polymerase mutants with reduced exonuclease activity. Proc Natl Acad Sci USA 2014; 111:17462–17467 [View Article] [PubMed]
     [Google Scholar]
  10. Loregian A, Coen DM. Selective anti-cytomegalovirus compounds discovered by screening for inhibitors of subunit interactions of the viral polymerase. Chem Biol 2006; 13:191–200 [View Article] [PubMed]
     [Google Scholar]
  11. Vernooij RW, Michael M, Colombijn JM, Owers DS, Webster AC et al. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2025; 1:CD005133 [View Article] [PubMed]
     [Google Scholar]
  12. Vernooij RW, Michael M, Ladhani M, Webster AC, Strippoli GF et al. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2024; 5:CD003774 [View Article] [PubMed]
     [Google Scholar]
  13. Sullivan V, Coen DM. Isolation of foscarnet-resistant human cytomegalovirus patterns of resistance and sensitivity to other antiviral drugs. J Infect Dis 1991; 164:781–784 [View Article] [PubMed]
     [Google Scholar]
  14. Shankar S, Pan J, Yang P, Bian Y, Oroszlán G et al. Viral DNA polymerase structures reveal mechanisms of antiviral drug resistance. Cell 2024; 187:5572–5586 [View Article] [PubMed]
     [Google Scholar]
  15. Freitas VR, Smee DF, Chernow M, Boehme R, Matthews TR et al. Activity of 9-(1,3-dihydroxy-2-propoxymethyl)guanine compared with that of acyclovir against human, monkey, and rodent cytomegaloviruses. Antimicrob Agents Chemother 1985; 28:240–245 [View Article]
     [Google Scholar]
  16. Smee DF, Martin JC, Verheyden JP, Matthews TR. Anti-herpesvirus activity of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine. Antimicrob Agents Chemother 1983; 23:676–682 [View Article] [PubMed]
     [Google Scholar]
  17. Fourgeaud J, Barry M, Bourgon N, Veyrenche N, Guilleminot T et al. Cytomegalovirus vertical transmission rate according to IgG avidity value and valacyclovir treatment of maternal primary infection in the first trimester of pregnancy. Clin Infect Dis 2025ciaf437 [View Article] [PubMed]
     [Google Scholar]
  18. Faure-Bardon V, Bouazza N, Benaboud S, Foissac F, Rouillon S et al. Quantification of maternal and fetal valaciclovir exposure in a pharmacokinetic study of cytomegalovirus-infected pregnant women treated to prevent vertical transmission. J Antimicrob Chemother 2025; 80:760–766 [View Article] [PubMed]
     [Google Scholar]
  19. Khalil A, Heath PT, Jones CE, Soe A, Ville YG et al. Congenital cytomegalovirus infection: update on screening, diagnosis and treatment: scientific impact paper no. 56. BJOG 2025; 132:e42–e52 [View Article] [PubMed]
     [Google Scholar]
  20. Bourgon N, Lopez R, Fourgeaud J, Guilleminot T, Bussières L et al. In utero treatment of congenital cytomegalovirus infection with valganciclovir: an observational study on safety and effectiveness. J Antimicrob Chemother 2024; 79:2500–2508 [View Article] [PubMed]
     [Google Scholar]
  21. Leruez-Ville M, Chatzakis C, Lilleri D, Blazquez-Gamero D, Alarcon A et al. Consensus recommendation for prenatal, neonatal and postnatal management of congenital cytomegalovirus infection from the European congenital infection initiative (ECCI). Lancet Reg Health Eur 2024; 40:100892 [View Article] [PubMed]
     [Google Scholar]
  22. Chatzakis C, Shahar-Nissan K, Faure-Bardon V, Picone O, Hadar E et al. The effect of valacyclovir on secondary prevention of congenital cytomegalovirus infection, following primary maternal infection acquired periconceptionally or in the first trimester of pregnancy. An individual patient data meta-analysis. Am J Obstet Gynecol 2024; 230:109–117 [View Article] [PubMed]
     [Google Scholar]
  23. Jacquemard F, Yamamoto M, Costa J-M, Romand S, Jaqz-Aigrain E et al. Maternal administration of valaciclovir in symptomatic intrauterine cytomegalovirus infection. BJOG 2007; 114:1113–1121 [View Article] [PubMed]
     [Google Scholar]
  24. Shahar-Nissan K, Pardo J, Peled O, Krause I, Bilavsky E et al. Valaciclovir to prevent vertical transmission of cytomegalovirus after maternal primary infection during pregnancy: a randomised, double-blind, placebo-controlled trial. Lancet 2020; 396:779–785 [View Article] [PubMed]
     [Google Scholar]
  25. Purifoy DJ, Beauchamp LM, de Miranda P, Ertl P, Lacey S et al. Review of research leading to new anti-herpesvirus agents in clinical development: valaciclovir hydrochloride (256U, the L-valyl ester of acyclovir) and 882C, a specific agent for varicella zoster virus. J Med Virol 1993; Suppl 1:139–145 [View Article] [PubMed]
     [Google Scholar]
  26. Stanton RJ, Prod’homme V, Purbhoo MA, Moore M, Aicheler RJ et al. HCMV pUL135 remodels the actin cytoskeleton to impair immune recognition of infected cells. Cell Host Microbe 2014; 16:201–214 [View Article]
     [Google Scholar]
  27. Hyde K, Sultana N, Tran AC, Bileckaja N, Donald CL et al. Limited replication of human cytomegalovirus in a trophoblast cell line. J Gen Virol 2021; 102:001683 [View Article] [PubMed]
     [Google Scholar]
  28. Dolan A, Cunningham C, Hector RD, Hassan-Walker AF, Lee L et al. Genetic content of wild-type human cytomegalovirus. J Gen Virol 2004; 85:1301–1312 [View Article] [PubMed]
     [Google Scholar]
  29. Tomasec P, Braud VM, Rickards C, Powell MB, McSharry BP et al. Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science 2000; 287:1031 [View Article] [PubMed]
     [Google Scholar]
  30. Stanton RJ, Baluchova K, Dargan DJ, Cunningham C, Sheehy O et al. Reconstruction of the complete human cytomegalovirus genome in a BAC reveals RL13 to be a potent inhibitor of replication. J Clin Invest 2010; 120:3191–3208 [View Article] [PubMed]
     [Google Scholar]
  31. Faulds D, Heel RC. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs 1990; 39:597–638 [View Article] [PubMed]
     [Google Scholar]
/content/journal/jgv/10.1099/jgv.0.002178
Loading
Inhibition of human cytomegalovirus replication by valaciclovir
J. Gen. Virol. 106, 002178 (2025); https://doi.org/10.1099/jgv.0.002178
/content/journal/jgv/10.1099/jgv.0.002178
/content/journal/jgv/10.1099/jgv.0.002178
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An error occurred
Approval was partially successful, following selected items could not be processed due to error